VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study

Abstract Purpose Unmethylated MGMT is a validated biomarker for temozolomide (TMZ) resistance and poor prognosis in glioblastoma. VAL-083 (dianhydrogalactitol; DAG) is a DNA-targeting agent that forms interstrand crosslinks at O6/N7-guanine, inducing double-strand breaks and cell death independently...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Chengcheng Guo, Qunying Yang, Meiling Deng, Xiaoling Qiu, Shaoxiong Wu, Xiaojing Du, Ke Sai, Ziyu Dai, Zhenghe Chen, Ji Zhang, Fuhua Lin, Chao Ke, Shaoyan Xi, Wanming Hu, Zhihuan Zhou, Jiawei Li, Xi Cao, Yixiang Liao, Yanchun Lv, Dennis Brown, John Langlands, Gregory Johnson, Jeffrey Bacha, Claire Kwan, Sarath Kanekal, Richard Schwartz, Zhongping Chen
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Springer 2025-12-01
Serie:	Discover Oncology
Soggetti:	VAL-083 Glioblastoma Radiation Newly-diagnose MGMT-unmethylated
Accesso online:	https://doi.org/10.1007/s12672-025-04235-y
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!